2712126-48-0
Chemical Structure
Imiquimod-d9
Synonym(s): R 837-d9
- CAS No.: 2712126-48-0
- Formula:C14H7D9N4
- Molecular Weight:249.36
IUPAC Name: 1-(2-(methyl-d3)propyl-1,1,2,3,3,3-d6)-1H-imidazo[4,5-c]quinolin-4-amine
InChIKey: DOUYETYNHWVLEO-UEZIPFSLSA-N
SMILES: NC1=NC2=CC=CC=C2C3=C1N=CN3C([2H])([2H])C([2H])(C([2H])([2H])[2H])C([2H])([2H])[2H]
Biological Activity: Imiquimod-d9 is deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Imiquimod-d9 | Imiquimod-d9 is deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Imiquimod (Standard) | ≥98% | Imiquimod (Standard) is the analytical standard of Imiquimod. This product is intended for research and analytical applications. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Imiquimod-d7 | Imiquimod-d7 (R 837-d7) is deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Imiquimod-d6 | Imiquimod-d6 is the deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Imiquimod | 99.97% | Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Athina Angelopoulou, et al. Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19. Environ Res. 2020 Sep; 188: 109858. [Content Brief]
